Document Detail


Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study.
MedLine Citation:
PMID:  19328570     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To characterize the relationship between pre-radiotherapy (18)Fluorodeoxyglucose (FDG) uptake in a tumour voxel, radiation dose and the probability to achieve metabolic control in the tumour voxel after radiotherapy. MATERIALS AND METHODS: Thirty-nine patients with inoperable stage I-III non-small cell lung cancer, treated with radiotherapy (RT) alone or sequential chemo radiation were analysed retrospectively. Twenty-two showed metabolic active areas in the tumour 3 months post-radiotherapy, which is known to be a surrogate for persistent local tumour failure and worse survival. Pre- and post-RT FDG-PET-CT scans were registered and the metabolic active zones within the tumour after RT were projected on the pre-RT scan. Multi-level logistic regression was performed to determine the relation between the FDG uptake if a voxel pre-RT and its metabolic state after RT. RESULTS: The probability that a voxel is metabolically controlled (mVCP), decreased significantly with increasing FDG uptake in a voxel (SUV) (OR=0.72), increasing tumour volume (20 cm(3)) (OR=0.89) and increasing dose (Gy) (OR=0.99). Inter-patient differences in mVCP were substantial. CONCLUSION: A methodology was presented to derive relationships between FDG uptake, dose and metabolic control. Although no strong dose effect relation was demonstrated, mVCP decreased with increasing FDG uptake and tumour volume.
Authors:
Steven F Petit; Hugo J W L Aerts; Judith G M van Loon; Claudia Offermann; Ruud Houben; Bjorn Winkens; Michel C Ollers; Philippe Lambin; Dirk De Ruysscher; André L A J Dekker
Publication Detail:
Type:  Journal Article     Date:  2009-03-26
Journal Detail:
Title:  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology     Volume:  91     ISSN:  1879-0887     ISO Abbreviation:  Radiother Oncol     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-25     Completed Date:  2009-09-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8407192     Medline TA:  Radiother Oncol     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  393-8     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. steven.petit@maastro.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carcinoma, Non-Small-Cell Lung / metabolism*,  pathology,  radiotherapy
Fluorodeoxyglucose F18 / pharmacokinetics
Humans
Logistic Models
Lung Neoplasms / metabolism*,  pathology,  radiotherapy
Neoplasm Staging
Radiation Injuries / prevention & control
Radiopharmaceuticals / pharmacokinetics
Radiotherapy Dosage
Tomography, Emission-Computed
Tomography, X-Ray Computed
Treatment Outcome
Tumor Burden
Chemical
Reg. No./Substance:
0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Air pollution and infant health: Lessons from New Jersey.
Next Document:  Comparison between the ideal reference dose level and the actual reference dose level from clinical ...